Biotech Stock Bubble Debate in 14 Charts
BOSTON (
) -- Checking in on the "Biotech Bubble: Yeah or Nay?" debate:
Before we start, let's agree the biotech sector is still having an unbelievable year.
data by
But biotech stocks have underperformed the broader market in the past month.
data by
Momentum-driven biotech stocks -- mostly small- and mid-cap -- have been hit with some serious selling over the past month. These were some of the sector's highest flyers, but not lately. I'm talking about stocks like:
Celldex Therapeutics
(CLDX) - Get Report
:
data by
Clovis Oncology
(CLVS) - Get Report
:
^NBI
data by
and
Immunomedics
(IMMU) - Get Report
:
data by
2013 is shaping up to be a record year for biotech IPOs, but not all of the stellar debuts have staying power.
Bluebird Bio
(BLUE) - Get Report
:
data by
Alcobra Pharma
(ADHD)
:
ADHD
data by
Onconova Therapeutics
(ONTX) - Get Report
:
data by
Stemline Therapeutics
(STML) - Get Report
:
data by
Some biotech IPOs keep moving higher, like...
Receptos
(RCPT)
RCPT
data by
and
Ambit BioSciences
(AMBI)
:
AMBI
data by
Big-cap biotech stocks are still performing strongly. Is there an investor flight to quality companies like
Gilead Sciences
(GILD) - Get Report
,
Amgen
(AMGN) - Get Report
,
Biogen Idec
(BIIB) - Get Report
and
Celgene
(CELG) - Get Report
?
data by
It's definitely NOT been a hard-knock life for orphan drug stocks in 2013:
AEGR
data by
But investors have sent orphans begging in the past month:
AEGR
data by
-- Reported by Adam Feuerstein in Boston.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
